期刊文献+

利用新型载体运转MDR1 siRNA以逆转胰腺癌化疗耐药性的研究 被引量:1

Reversal of chemoresistance in pancreatic cancer line by delivering an MDR1 small interfering RNA (siRNA) by a adenoassociated Vector
下载PDF
导出
摘要 目的:以新型载体运转MDR1 siRNA导入胰腺癌细胞株后,观察其多药物耐药基因(MDR1)的表达及其对胰腺癌化疗耐药性的影响。方法:采用RNA干扰技术,构建可用于包装成自我复制rAAV病毒载体的质粒,以运转不同长度的MDR1 siRNA。采用实时PCR检测MDR1 mRNA的表达,Western印迹法检测总P-糖基化蛋白(P-gp)的表达水平,用流式细胞仪检测细胞表面的P-gp表达,并从不同层面检测胰腺癌细胞株P-gp表达的抑制率,从而筛选出最佳的质粒载体。采用MTT检测IC50值,进行各载体逆转胰腺癌细胞株化疗耐药性的研究。结果:拟用于构建自我复制rAAV病毒载体的25-mer MDR1 siRNA质粒能有效地将目的基因MDR1 siRNA导入胰腺癌细胞株,并予稳定的表达,发挥作用。导入胰腺癌细胞株的MDR1 siRNA能有效地在mRNA水平上沉默MDR1基因,显著抑制其表达,使其蛋白产物P-gp的表达明显减少,及其在细胞膜上的数量显著降低。结果能有效、显著地逆转胰腺癌细胞株的化疗耐药性,转染前SW1990/ADM细胞对ADM的IC50值约是转染后的50倍。结论:采用可用于构建新型sc-rAAV载体的质粒作为投递siRNA的工具,并选择MDR1为研究靶点,通过实验证实该策略在逆转胰腺癌化疗耐药性中的有效性。 Objective The inhibitory effect of siRNA has been shown to counteract the resistance to chemotherapy by suppressing the expression of MDR-1 gene-encoded P-gp in pancreatic cancer.Our research involues an investigation of the reversal of chemoresistance a pancreatic cancer cell line by delivering an MDR1 siRNA by self-complementary AAV(scAAV),a new style vector.Methods The sequences of the hairpin siRNAs for anti-MDR1 25-mer and 28-mer,mismatch MDR1,targeting MDR1 mRNA at nt 1545-1565 or their extensions were synthesized and inserted into BamHI-HindIII linearized pSilencer 2.1-U6 hygro vector.The plasmid and the control plasmid were stably transfected into human pancreatic cancer cell lines SW1990/ADM and SW1990.RNA extraction and real-time RT-PCR were performed to investigate the effect of vectors in the mRNA level.Total cellular P-glycoprotein by was detected Western blot.P-glycoprotein expression on cell surface was measured by flow cytometry.MTT was applied to the chemo-sensitivity test of chemotherapeutic agents on tumor cell lines.Results The results showed correlated degrees of reduction in the MDR1 mRNA level and total P-glycoprotein level in groups of 25-mer and 28-mer.The 25-mer group was found to be more effective than the latter.In the control groups,the expressed levels of MDR1 mRNA and P-glycoprotein were similar to those of untreated controls.And the result of MTT showed ADM-response profiles of the 25-mer group to be significantly left-shifted,with IC50 values of 1.5.Conclusions Based on this experience,we extrapolate that the technique of siRNA and this type of vector may be a valuable tool in therapy of pancreatic cancer.
出处 《外科理论与实践》 2010年第4期416-422,共7页 Journal of Surgery Concepts & Practice
基金 国家自然科学基金资助项目(3057181230772113)
关键词 胰腺癌化疗 多药物耐药 化疗耐药 RNA干扰 sc-rAAV病毒载体 Pancreatic cancer MDR1 Chemoresistance siRNA sc-rAAV
  • 相关文献

参考文献15

  • 1赵玉沛.重视早期诊断是攻克胰腺癌的关键[J].中华外科杂志,2001,39(4):261-262. 被引量:17
  • 2Zalatnai A,Molnár J.Review.Molecular background of chemoresistance in pancreatic cancer[J].In Vivo,2007,21(2):339-347.
  • 3Najlah M,Freeman S,Attwood D,et al.Synthesis and assessment of first-generation polyamidoamine dendrimer prodrugs to enhance the cellular permeability of P-gp substrates[J].Bioconjug Chem,2007,18(3):937-946.
  • 4Takara K,Sakaeda T,Okumura K.An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy[J].Curr Pharm Des,2006,12(3):273-286.
  • 5Zalatnai A,Molnár J.Effect of SILA-409,a new organosilicon multidrug resistance modifier,on human pancreatic cancer xenografts[J].In Vivo,2006,20(1):137-140.
  • 6Wu JQ,Zhao WH,Li Y,et al.Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy[J].Virology,2007,368(2):309-316.
  • 7张立阳,赵玉沛,吴元德,廖泉,郭俊超,刘子文,张太平.胰腺癌阿霉素耐药细胞株SW1990/ADM的建立及其耐药机理研究[J].中国普外基础与临床杂志,2005,12(1):46-50. 被引量:15
  • 8Sauna ZE,Kim IW,Ambudkar SV.Genomics and the mechanism of P-glycoprotein(ABCB1)[J].J Bioenerg Biomembr,2007,39(5-6):481--487.
  • 9Wu H,Hait WN,Yang JM.Small interfering RNA-induced suppression of MDR1(P-glycoprotein)restores sensitivity to multidrug-resistant cancer cells[J].Cancer Res,2003,63(7):1515-1519.
  • 10Stephens B,Han H,Hostetter G,et al.Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phasphorylation and reduced clonogenicity of pancreatic cancer cells[J].Mol Cancer Ther,2008,7(1):202-210.

二级参考文献13

  • 1梁正东,卞度宏.卵巢癌细胞对顺铂耐药及其逆转的实验研究[J].中华妇产科杂志,1996,31(2):75-78. 被引量:21
  • 2Moran E, Cleary I, Larkin AM, etal. Co-expression of MDR-assoeiated markers, ineluding P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42 [J]. Eur J Cancer, 1997, 33(4) : 652.
  • 3Uchiyama-Kokubu N, Watanabe T. Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance [J]. Anticancer Drugs, 2001; 12(9): 769.
  • 4Fillpits M, Suehomel RW, Dekan G, et al. Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas [J]. Br J Cancer, 1997, 75(2): 208.
  • 5Jokoby WB. Methods in enzymology [M]. New York: Acad Press,1979: 150.
  • 6Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill [J]. J Immunol Methods, 1989, 119(2) : 203.
  • 7Biedler JL, Riehm H. Cellular resistance to actinomyein D in Chinese hamster cells in vitro : cross-resistance, radioautographic, and cytogenetlc studies [J]. Cancer Res, 1970:30(4) :1174.
  • 8Suwa H, Ohshio G, Arao S, etal. Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis[J]. Jpn J Cancer Res, 1996; 87(6):641.
  • 9Yu DS, Chang SY, Ma CP. Characterization and modulation of transitional cell carcinoma cell lines with acquired multidrug resistanee[J]. Br J Urol, 1998, 81(2):234.
  • 10E. P. DiMagno. Pancreatic Cancer: Clinical Presentation, Pitfalls and Early Clues[J] 1999,Annals of Oncology(4):140~142

共引文献30

同被引文献26

  • 1Siegel R*Naishadham D,Jemal AL. Cancer statistics,20l[J]. CACancer J Clin,2012,62(1) :10-29.
  • 2Xu MM,Mao GX* Liu J,et al. Low expression of the Fox04 genemay contribute to the phenomenon of EMT in non-small cell lungcancer[J]. Asian Pac J Cancer Prev,2014,15(9) :4013-4018.
  • 3Yin M,Yan J, Voutsian A,et al. No evidence of an association ofERCC1 and ERCC2 polymorphisms with clinical outcomes ofplatinum-based chemotherapies in non-small cell lung cancer: ameta-analysis[J]. Lung Cancer,2011,72(3) :370-377.
  • 4Orelli B,McClendon TB, Tsodikov OV. et al. The XPA-bindingdomain of ERCC1 is required for nucleotide excision repair butnot other DNA repair pathways[J], Biol Chem, 2010,285 ( 6):3705-3712.
  • 5Laine JP,Mocquet V,Bonfanti M,et al. Common XPD(ERCC2) pol-ymorphisms have no mesurable effect on nucleotide excision repairand basal transcription[J]. DNA Repair,2007,6(9) : 1264-1270.
  • 6Yu H,Zou Y, Jiang L, et al. Induction of apoptosis in non-smallcell lung cancer by downregulation of MDM2 using pH-respon-sive PMPC-b-PDPA/siRNA complex nanoparticles [J], Biomate-rials, 2013 ,34C11) : 2738-2747.
  • 7Barr MP,Gray SG,Hoffmann AC, et al. Generation and characterisa-tion of Cisplatin-resistant non-small cell lung cancer cell lines displa-ying a stem-like signature[J]. PLoS One,2013,8(1) : 1-19.
  • 8Pan B,Zheng S,Liu C,et al. Suppression of IGHG1 gene expres-sion by siRNA leads to growth inhibition and apoptosis inductionin human prostate cajicer cell [J], Mol Biol Rep,2013 ,40(1) : 27-33.
  • 9Chen CK, Law WC, Aalinkeel R, et al. Well-defined degradablecationic polylactide as nanocarrier for the delivery of siRNA tosilence angiogenesis in prostate cancer[J], Adv Healthcare Ma-ter, 2012 ,1(6) : 751-761.
  • 10Ueda S,Shirabe K, Morita K,et al. Evaluation of ERCC1 expres-sion for Cisplatin sensitivity in human hepatocellular carcinoma[J], Ann Surg Oncol,2011,18(4) : 1204-1211.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部